WESTFIELD, N.J., Oct. 17, 2016 /PRNewswire/ -- Relburn-Metabolomics, Inc. announced that the Company has achieved key milestones in finalizing its medicinal chemistry program that targets chronic gout. Relburn scientists have synthesized derivatives of the Company's prototype drug that act at low nanomolar concentrations against two key regulators of uric acid, the proximate cause of gout. The Company has also effectively altered the activity profile of its leads to reflect the latest clinical and safety experience with standard monofunctional drugs. In clinical studies comprising more than 350 patients, the Company's prototype induced striking reductions in serum uric acid, including in all patients with elevated baseline levels.
"The high potency of our unique bifunctional inhibitors are clearly responsible for the striking control of uric acid observed in patients," said Dr. Raymond P. Warrell, Jr., Relburn's Chief Executive Officer. "We have now filed 4 worldwide, wholly owned patents on compositions and processes, and we expect to nominate a clinical lead for IND-enabling studies in the near future."